Endari
Named-patient access overview. Endari is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Endari (L-glutamine oral powder) is an FDA-approved therapy for sickle cell disease developed by Emmaus Life Sciences. The US Food and Drug Administration approved Endari in July 2017 for the reduction of acute complications of sickle cell disease in adult and paediatric patients aged 5 years and older. It is dosed orally as a powder mixed with a beverage or soft food, typically 5 grams to 15 grams twice daily based on body weight.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Endari
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Endari is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Endari in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Endari
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.